{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:53:42Z","timestamp":1784159622835,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13555-022-00832-9","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T17:03:57Z","timestamp":1668877437000},"page":"207-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Economic Burden of Comorbidities in Patients with Psoriasis in the USA"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-1892","authenticated-orcid":false,"given":"Jashin J.","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2561-4776","authenticated-orcid":false,"given":"Manasi","family":"Suryavanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3636-3423","authenticated-orcid":false,"given":"Vardhaman","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-3065","authenticated-orcid":false,"given":"Lauren","family":"Seigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"832_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/1472-6963-14-344","volume":"14","author":"A Mustonen","year":"2014","unstructured":"Mustonen A, Leino M, Mattila K, Koulu L, Tuominen R. Treatment costs of psoriasis in a tertiary-level clinic. BMC Health Serv Res. 2014;14:344.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"832_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jaad.2020.10.035","volume":"84","author":"J Liu","year":"2021","unstructured":"Liu J, Thatiparthi A, Martin A, Egeberg A, Wu JJ. Prevalence of psoriasis among adults in the US 2009\u20132010 and 2013\u20132014 National Health and Nutrition Examination Surveys. J Am Acad Dermatol. 2021;84(3):767\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"832_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"key":"832_CR4","unstructured":"Global Report on Psoriasis. Switzerland: World Health Organization; 2016."},{"issue":"10","key":"832_CR5","first-page":"874","volume":"21","author":"SR Feldman","year":"2015","unstructured":"Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874\u201388.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"832_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1468-3083.2010.03730.x","volume":"25","author":"AB Kimball","year":"2011","unstructured":"Kimball AB, Gu\u00e9rin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25(2):157\u201363.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"832_CR7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1185\/030079904X15192","volume":"20","author":"WH Crown","year":"2004","unstructured":"Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004;20(12):1929\u201336.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"832_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/jcm10051031","volume":"10","author":"A Ruggiero","year":"2021","unstructured":"Ruggiero A, Fabbrocini G, Cacciapuoti S, Cinelli E, Gallo L, Megna M. Ocular manifestations in psoriasis screening (OcMaPS) questionnaire: a useful tool to reveal misdiagnosed ocular involvement in psoriasis. J Clin Med. 2021;10(5):1031.","journal-title":"J Clin Med"},{"issue":"10","key":"832_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","volume":"149","author":"H Yeung","year":"2013","unstructured":"Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173\u20139.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"832_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"832_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","volume":"151","author":"EA Brezinski","year":"2015","unstructured":"Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651\u20138.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"832_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/13696998.2019.1571500","volume":"22","author":"JJ Wu","year":"2019","unstructured":"Wu JJ, Pelletier C, Ung B, Tian M. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. J Med Econ. 2019;22(4):365\u201371.","journal-title":"J Med Econ"},{"issue":"4","key":"832_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1365-2133.2010.09944.x","volume":"163","author":"A Fonia","year":"2010","unstructured":"Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163(4):807\u201316.","journal-title":"Br J Dermatol"},{"key":"832_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41927-020-0115-2","volume":"4","author":"DP Hudesman","year":"2020","unstructured":"Hudesman DP, Chakravarty SD, Emond B, et al. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. BMC Rheumatol. 2020;4:16.","journal-title":"BMC Rheumatol"},{"issue":"1","key":"832_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40744-021-00277-0","volume":"8","author":"A Schwarting","year":"2021","unstructured":"Schwarting A, Friedel H, Garal-Pantaler E, et al. The burden of systemic lupus erythematosus in Germany: incidence, prevalence, and healthcare resource utilization. Rheumatol Ther. 2021;8(1):375\u201393.","journal-title":"Rheumatol Ther"},{"key":"832_CR16","doi-asserted-by":"crossref","unstructured":"Feldman SR, Tian H, Wang X, Germino R. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large U.S. claims database. J Manag Care Spec Pharm. 2018;25(4):479\u201388.","DOI":"10.18553\/jmcp.2018.18308"},{"key":"832_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/CEOR.S251775","volume":"12","author":"DL Kaplan","year":"2020","unstructured":"Kaplan DL, Ung BL, Pelletier C, Udeze C, Khilfeh I, Tian M. Switch rates and total cost of care associated with apremilast and biologic therapies in biologic-naive patients with plaque psoriasis. Clinicoecon Outcomes Res. 2020;12:369\u201377.","journal-title":"Clinicoecon Outcomes Res"},{"key":"832_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12891-016-1102-z","volume":"17","author":"JB Palmer","year":"2016","unstructured":"Palmer JB, Li Y, Herrera V, Liao M, Tran M, Ozturk ZE. Treatment patterns and costs for anti-TNF\u03b1 biologic therapy in patients with psoriatic arthritis. BMC Musculoskelet Disord. 2016;17:261.","journal-title":"BMC Musculoskelet Disord"},{"issue":"11","key":"832_CR19","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1007\/s12325-019-01095-1","volume":"36","author":"GH Long","year":"2019","unstructured":"Long GH, Tatro AR, Oh YS, Reddy SR, Ananthakrishnan AN. Analysis of safety, medical resource utilization, and treatment costs by drug class for management of inflammatory bowel disease in the United States based on insurance claims data. Adv Ther. 2019;36(11):3079\u201395.","journal-title":"Adv Ther"},{"issue":"6","key":"832_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00403-021-02200-7","volume":"314","author":"M Megna","year":"2022","unstructured":"Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619\u201323.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"832_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15214","volume":"35","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study. Dermatol Ther. 2022;35(1): e15214.","journal-title":"Dermatol Ther"},{"issue":"3","key":"832_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/ced.14979","volume":"47","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"832_CR23","volume":"35","author":"G Caldarola","year":"2022","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6): e15488.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00832-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T18:31:29Z","timestamp":1673029889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00832-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00832-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}